Document is current
Any future updates will be listed below
-
Authors
Alexander, Tobias https://orcid.org/0000-0003-1193-0097
Roldan, Elisa https://orcid.org/0000-0001-7242-170X
Del Papa, Nicoletta https://orcid.org/0000-0003-1549-8852
Farge, Dominique https://orcid.org/0000-0002-4041-1352
Henes, Jörg
Marjanovic, Zora https://orcid.org/0000-0002-5391-5875
Puyade, Mathieu https://orcid.org/0000-0002-5639-0138
Snowden, John A. https://orcid.org/0000-0001-6819-3476
Spierings, Julia https://orcid.org/0000-0002-2546-312X
de Vries-Bouwstra, Jeska K.
Onida, Francesco https://orcid.org/0000-0002-2991-3474
Ruggeri, Annalisa https://orcid.org/0000-0002-7261-2765
Sánchez-Ortega, Isabel https://orcid.org/0009-0005-5519-9154
Burt, Richard https://orcid.org/0000-0002-0922-4145
Cervera, Ricard
Doria, Andrea https://orcid.org/0000-0003-0548-4983
Moore, John
Oliveira, Maria Carolina https://orcid.org/0000-0003-0691-2222
Pugnet, Grégory https://orcid.org/0000-0002-2621-204X
Rimar, Doron
Schmalzing, Marc
Yakoub-Agha, Ibrahim https://orcid.org/0000-0003-4524-8782
Greco, Raffaella https://orcid.org/0000-0002-6117-5328
- License Information
-
More Information
Article History
Received: 9 May 2025
Revised: 10 July 2025
Accepted: 4 August 2025
First Online: 20 August 2025
Competing interests
: TA received Honoria from Abbvie, Amgen, AstraZeneca and GSK study support from Johnson & Johnson. RG discloses speaking honoraria from Biotest, Pfizer, Medac, Neovii, Kyverna and Magenta. RB is CEO of Genani Corporation, Chicago, Illinois. FM received honoraria & Travel Support from BMS, Janssen, Kite/Gilead, Miltenyi, Novartis, Received Research Support from Kite/Gilead. JAS discloses consultancy for BMS, Medac, Vertex and Jazz. JH discloses consultancy for Miltenyi and Neovii. JS discloses research support from Boehringer Ingelheim and Miltenyi. RC discloses consultancy for AstraZeneca, Celgene, GSK, Janssen, ElyLilly, Pfizer, UCB, Rubió and Werfen. PA reports no conflict of interest; he discloses travel support and speaker honoraria from unrestricted educational activities organized by Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis and consulting to Magenta Therapeutics, Jasper Therapeutics and Cellerys AG. ER discloses speaking honoraria by Janssen Pharmaceutica. AR discloses speaker honoraria from Gilead. The remaining authors have nothing to declare. JM discloses speaker honoria from Medac and Pfizer. JVR discloses speaker honoraria from Janssen-Cilag, Boehringer-Ingelheim, Pfizer, AstraZeneca, BMS, UCB; consultancy honoraria from Abbvie, Janssen, Boehringer- Ingelheim, and grant/research support from ReumaNederland, Janssen-Cilag, Galapagos, Roche; all payments were made to the institution. GP reports no conflict of interest; he discloses travel support and speaker honoraria from Abbvie, Astra-Zeneca, Novartis, Amgen, GSK, Pfizer, Boehringer Ingelheim, Amicus. None of the mentioned conflicts of interest were related to financing of the content of this manuscript.
: All methods were performed in accordance with the relevant guidelines and regulations. This study was approved by the Autoimmune Diseases Working Party of the EBMT.
